Clinical prognostic value of the SMYD2/3 as new epigenetic biomarkers in solid cancer patients: a systematic review and meta-analysis.
Mahdieh RazmiAyna YazdanpanahShahroo Etemad-MoghadamMojgan AlaeddiniSabrina AngeliniLeila EiniPublished in: Expert review of molecular diagnostics (2022)
Enhanced SMYD2/3 expression may be an unfavorable clinical prognostic factor in different solid cancer types.